Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study

Clin Infect Dis. 2024 Jan 25;78(1):27-30. doi: 10.1093/cid/ciad476.

Abstract

In a propensity-score-weighted cohort of 183 adults with carbapenem-resistant Enterobacterales bacteremia at 24 US hospitals, patients receiving short courses of active therapy (7-10 days, median 9 days) experienced similar odds of recurrent bacteremia or death within 30 days as those receiving prolonged courses of active therapy (14-21 days, median 14 days).

Keywords: bacteremia; carbapenem-resistant Enterobacterales; ceftazidime-avibactam; meropenem-vaborbactam.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / drug therapy
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use
  • Ceftazidime
  • Drug Combinations
  • Hospitals
  • Humans
  • Microbial Sensitivity Tests
  • Sepsis*

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Drug Combinations
  • Ceftazidime